Clinical trial · Interventional
Evaluation of a Personalised Survivorship Care Plan App for Patients With Melanoma
Personalised Survivorship Care for Patients With Melanoma: A Multicenter Randomised Controlled Trial of the Survivorship Care Plan App
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A multicentre randomised controlled trial (RCT) will be conducted to evaluate the effectiveness of the digital personalised Melanoma Survivorship Care Plan (SCP) app. A total of hundred-eighty melanoma patients (stage I and II) will be randomised to receive either the SCP Melanoma app or usual care. The app provides survivors with personalized healthcare information on diagnosis, treatment and follow-up and supportive care, tailored to their melanoma stage and phase and information needs.Through questionnaires, medical file records, patient-reported outcomes and use of medical care will be evaluated. In addition, log-data, questionnaires and interviews will be used to evaluate the process of the uptake and implementation of the digital SCP.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Digizorg Melanoma app | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Intervention group
- description
- Participants receive access to the Digizorg Melanoma app, on top of care as usual.
- interventionNames
- Device: Digizorg Melanoma app
- type
- NO_INTERVENTION
- label
- Control group
- description
- Participants have access to care as usual, but have no access to the Digizorg Melanoma app and its functionalities.
Primary outcomes (1)
- measure
- Patient empowerment
- timeFrame
- 1 year after inclusion
- description
- The extent to which patients are able to cope with their own condition. This is a result of understanding by the patient of his/her role, acquisition by patients of sufficient knowledge to be able to engage with their healthcare provider, the skills of the patient skills and the presence of a facilitating environment. This outcome is measured through a scaled questionnaire (Health Education Impact Questionnaire), on which higher scores indicate a more health-conscious, self-monitored and empowered self.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18 years or older * Patients who have received a primary diagnosis of cutaneous melanoma stage I to II in the past 0-4 months Exclusion Criteria: * Patients with irresectable stage III melanoma, patients receiving neo-adjuvant treatment and patients with stage IV melanoma. * Patients who do not have (sufficient) command of the Dutch language.
References
Publications (0)
Data not yet available